Key Points
- Adaptive Biotechnologies insider Francis Lo sold 39,741 shares on June 4 at an average price of $17.49, totaling about $695,070. After the sale, he still held 250,934 shares, and the transaction was made under a pre-arranged Rule 10b5-1 plan.
- The company reported stronger-than-expected first-quarter results, posting an EPS loss of $0.13 versus estimates for a $0.16 loss and revenue of $70.87 million versus $61.03 million expected. Revenue rose 35.1% from a year earlier.
- Analyst sentiment remains mixed but generally positive, with six Buy ratings and an average target price of $19.57. Shares opened at $16.70, below the consensus target but near the middle of the stock’s 52-week range.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Susan Bobulsky sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00. Following the transaction, the insider directly owned 416,775 shares of the company's stock, valued at $7,501,950. The trade was a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Wednesday, March 11th, Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.17, for a total transaction of $544,421.46.
Adaptive Biotechnologies Stock Performance
NASDAQ:ADPT opened at $16.70 on Tuesday. The stock has a market capitalization of $2.67 billion, a P/E ratio of -50.61 and a beta of 2.16. The company has a 50 day moving average price of $14.22 and a 200 day moving average price of $15.65. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.90 and a fifty-two week high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm's quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) EPS. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Adaptive Biotechnologies
A number of hedge funds and other institutional investors have recently modified their holdings of ADPT. AQR Capital Management LLC raised its holdings in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock valued at $2,265,000 after purchasing an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock valued at $511,000 after purchasing an additional 2,914 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at $93,000. New York State Common Retirement Fund raised its holdings in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company's stock valued at $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company's stock valued at $4,417,000 after purchasing an additional 333,379 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
ADPT has been the topic of a number of research reports. Wall Street Zen lowered shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Guggenheim reiterated a "buy" rating and set a $21.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. TD Cowen increased their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday, May 6th. Finally, BTIG Research reiterated a "buy" rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $19.57.
View Our Latest Research Report on ADPT
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
